Market Overview

UPDATE: Jefferies Raises PT on Merck & Co. Following Global Pharma Review

Share:
Related MRK
Merck Gets Breakthrough Therapy Status From FDA And PRIME Status From EMA For Investigational Ebola Zaire Vaccine
Merck Presents Data On Its Investigational Once-Daily Formulation Of ISENTRESS
July Basic Materials: Coal Tops By Yield But Cellulose, Carbon, Copper, And Chemicals Are Best By Brokers (Seeking Alpha)

In a report published Friday, Jefferies analyst Jeffrey Holford reiterated a Buy rating on Merck & Co. (NYSE: MRK), and raised the price target from $54.00 to $56.00.

In the report, Jefferies noted, “We reiterate Novartis as our Top European and Global Pick with positive growth inflection potential in 2014 and significant restructuring optionality being key drivers. Abbott is our Top US Pick for similar reasons. We highlight Roche, Sanofi and AbbVie as potentially offering particularly attractive entry points following the recent sell-off. AstraZeneca is now our Least Preferred stock.”

Merck & Co. closed on Thursday at $48.73.

Latest Ratings for MRK

DateFirmActionFromTo
Jul 2016BMO CapitalDowngradesOutperformMarket Perform
Jul 2016JefferiesMaintainsHold
Jun 2016JefferiesMaintainsHold

View More Analyst Ratings for MRK
View the Latest Analyst Ratings

Posted-In: Jeffrey HolfordAnalyst Color Price Target Analyst Ratings

 

Related Articles (MRK)

View Comments and Join the Discussion!